Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Biomedical innovation is dependent on a reliable supply of reagents in the fields of nucleic acid production, biologics safety testing and protein detection. From inventive startups to many of the world's leading biopharma, vaccine, diagnostics and cell and gene therapy companies, customers turn to Maravai to address their complex discovery challenges and help them streamline and scale from research through clinical trials to commercialization.
TriLink BioTechnologies is a global leader in RNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA capping technology, and CDMO services ranging from research to GMP grades. Glen Research leads in specialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applications. Cygnus Technologies developed the market for bioprocess impurity detection, process-related impurity analytics and viral clearance prior to human trials, regulatory approval and commercial release. Vector Laboratories is the pioneer of protein labeling and detection reagents for immunohistochemistry, immunofluorescence, glycobiology and bioconjugation.
Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV™, Sterling™, Glen Pak™, Glen Gel-Pak™, Poly-Pak™, VECTASTAIN® and VECTASHIELD®.
Maravai's portfolio companies are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications.